Archive for the 'Doxorubicin' Category
November 5th, 2008. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study
Conclusion: The treatment yields good results with a high number of responses and long survival, and a low toxicity. The long survival of the epitheloid subgroup with good prognostic factors is as good as or even better than some studies on radical surgery or multimodal treatment, underlining the need of randomized studies to evaluate such treatment options.
Posted in Carboplatin, Chemotherapy, Determining Efficacy, Doxorubicin, Epithelioid, Full Archive, Gemcitabine (Gemzar), Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 9th, 2008. Peritoneal Mesothelioma
To date there have been no universally accepted treatments for MPM. Unless referred to a specialty center, patients are routinely treated with pemetrexed and cisplatin which has been shown to increase survival in pleural mesothelioma.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Pemetrexed (Alimta), Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma:, mitomycin-C | 1 Comment »
August 22nd, 2008. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy
LHIPEC could be a good therapeutic option to palliate malignant ascites from mesothelioma in cases not eligible for a radical treatment. Further studies are needed to standardize dosage and perfusion parameters.
July 26th, 2008. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin
Conclusions: Doxorubicin shows characteristics favorable for intracavitary administration with sequestration of doxorubicin in cancer nodules.
Posted in Chemotherapy, Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Intrapleural Chemotherapy, Peritoneal (Abdominal Mesothelioma), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 28th, 2008. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy
Conclusions: We report that HIPEC with PLD following maximal cytoreduction in patients with advanced abdominal-only gastrointestinal or gynecologic malignancies is well tolerated. Encouraging survival after cytoreduction and HIPEC with PLD suggest that a phase II trial to verify activity is indicated.
April 10th, 2008. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Conclusion: Definitive eradication by means of cytoreduction and HIPEC seems a safe and effective therapeutic option for MPM.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 4th, 2008. Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1{alpha}
These effects were prevented by the coincubation with the cell-permeating iron salt ferric nitrilotriacetate (FeNTA), which caused an increase of intracellular iron bioavailability, checked as increased activity of the iron regulatory protein-1 (IRP-1). Crocidolite, dexrazoxane and hypoxia induce doxorubicin resistance in HMM cells by increasing HIF-1{alpha} activity, through an iron-sensitive mechanism.
April 1st, 2008. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma
Conclusion: Based on the results of this study, intensive multimodality therapy appears feasible and effective in this group of patients.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment: | No Comments »
January 25th, 2008. Ribonucleases as novel chemotherapeutics: the ranpirnase example
The basis for its specific toxicity for cancer cells is not known. This review describes the development of ranpirnase as a cancer chemotherapeutic agent.
July 31st, 2007. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Conclusions: MPM and WDPPM are borderline tumors capable of transformation into potentially lethal processes. Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Diffuse mesothelioma, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 20th, 2007. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin
Conclusions: Early cardiotoxicity is limited after this treatment modality using substantial doses of doxorubicin and cisplatin. Hence, this study suggests that intrathoracic chemotherapy with doxorubicin and/or cisplatin may be used for primary and secondary pleural malignancies, even immediately after extensive thoracic surgery, without concern of severe early cardiotoxicity.
February 28th, 2007. Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell.
6 423 515 B1) entitled 'Methods of Making Nucleic Acids Encoding Ribonucleases'. This patent is effective until 2020.
September 6th, 2006. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress
This offers a possible mechanism of action of selenite treatment. Our findings suggest that selenite is a promising new drug for the treatment of malignant mesothelioma.
June 14th, 2006. Cytoreductive surgery followed by intra peritoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: morbidity and mortality with closed abdomen technique
Conclusions: CRS+ IPHP presented acceptable morbidity 3/4 toxicity and mortality rates what support the need to be tested in prospective phase III clinical trial.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 25th, 2006. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites
Conclusions: This method resulted in benefit for those peritoneal carcinomatosis patients with debilitating malignant ascites who were excluded from cytoreductive surgery. Proficiency in laparoscopic staging procedures and experience in the management of carcinomatosis and intraperitoneal hyperthermic chemotherapy (IPHC) are required for the success of the procedure.
March 27th, 2006. Ranpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma
Standard first-line treatment for MM has recently been established with an antifolate and cisplatin. At present, a Phase III trial of doxorubicin with or without ranpirnase is nearing completion in MM patients without prior chemotherapy or one prior chemotherapy regimen.
February 28th, 2006. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
Conclusion: Sorafenib 400 mg bid plus doxorubicin 60 mg/m2 was well tolerated. The increased doxorubicin exposure with sorafenib 400 mg bid did not result in significantly increased toxicity; low patient numbers make the clinical significance of this unclear. These promising efficacy results justify further clinical investigation.
February 6th, 2006. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma
Both the Rho kinase inhibitor Y27632 and the RhoA inhibitor toxin B (from Clostridium difficile) mimicked the statins' effects, enhancing doxorubicin accumulation, NO synthesis and IKK phosphorylation and decreasing the amount of IkB in HMM cells. Simvastatin, Y27632 and toxin B elicited tyrosine nitration in the P-glycoprotein, thus providing a likely mechanism by which NO reverts the doxorubicin resistance in HMM cells.
November 28th, 2005. Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase
Phase II tumor-specific trials investigated the activity of ranpirnase in malignant mesothelioma, breast cancer, non-small cell lung cancer, and renal cell cancer. A Phase III randomized study in malignant mesothelioma patients compares the combination of ranpirnase plus doxorubicin to doxorubicin monotherapy.
September 1st, 2005. Mesothelioma: treatment and survival of a patient population and review of the literature
Conclusion: Malignant mesothelioma of the pleura and intraperitoneum is a slow-growing disease which is indicated by the long survival, despite the failure of chemotherapy, radiation therapy and surgery.
Posted in Carboplatin, Chemotherapy, Cisplatin (Platinol ®), Cyclophosphamide, Determining Efficacy, Doxorubicin, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Peritoneal (Abdominal Mesothelioma), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
|
|  |
